![]() | Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 3,201 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 19 May 2024 by
DoubleGrazing (
talk). The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you. This submission does not appear to be written in
the formal tone expected of an encyclopedia article. Entries should be written from a
neutral point of view, and should refer to a range of
independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid
peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. | ![]() |
Mohammad Arif Hossain | |
---|---|
![]() | |
Born | |
Citizenship | Japanese |
Education | Osaka University School of Medicine |
Employer | JCR pharmaceuticals ltd. |
Known for | Research on inherited metabolic diseases and Lysosomal storage disease |
Awards | JSIMD Young Investigator Award, 2019 |
Dr. Mohammad Arif Hossain, also known as Dr. Hossain, is a research scientist renowned for his contributions to the field of lysosomal storage disorders (LSDs). His research has led to advancements in diagnostic techniques and therapeutic approaches, including the development of chemical chaperone therapies and novel biomarker-based methods.
Hossain's research investigates lysosomal storage diseases (LSDs) and other Inborn errors of metabolism (IEMs), with a focus on improving diagnosis and treatment. His work has demonstrably contributed to understanding Krabbe disease, galactosialidosis, Fabry disease, and others. He has utilized patient-specific motor neurons derived from induced pluripotent stem cells (iPSCs) to study metachromatic leukodystrophy (MLD) and analyzed caregiver perspectives on treatment for mucopolysaccharidosis II (MPS II). Hossain has developed cellular models using patient-specific iPSCs to study Niemann-Pick disease type C (NPC) and established a diagnostic approach for X-linked adrenoleukodystrophy (X-ALD) in Japan. His research has yielded valuable insights into various LSDs and IEMs, including the therapeutic potential of genistein in mucolipidosis II and the characterization of enzymes for neuronal ceroid lipofuscinosis (NCL) types 1 and 2.
Hossain has authored more than 26 peer-reviewed articles. [1] in scientific journals. His efforts in uncovering the mechanisms and treatments for LSDs have earned him global recognition. He has been honored with the JSIMD Young Investigator Award [2] in 2019, the JHG Young Scientist Award in 2017 [3], and the Kunihiko Suzuki Award [4] in 2017.In 2020, he was awarded the World Symposium Young Investigator Award [5]
Since 2021 Hossain working as a medical advisor at JCR Pharmaceuticals Ltd. (JCRファーマ) to focus on developing enzyme replacement therapy (ERT) for various LSDs.
Hossain, was raised in a large Bangladeshi family with a strong emphasis on education, excelled academically. He pursued medicine, encountering diagnostic limitations in pediatrics that fueled his research drive. After a Ph.D. in Japan, his research focused on LSDs, leading to a novel therapeutic approach for Krabbe disease and Galactosialidosis.
Beyond science, Hossain's life reflects deep faith and a commitment to public health. He previously led an anti-smoking organization and actively promotes child health through media and online platforms. Currently residing in Japan with his family, he balances research with his role as a devoted husband and father.
• FRCP, Royal College of Physicians and Surgeons, Glasgow, UK September 2021
• FRCPCH, Royal College of Pediatrics and Child Health, London, UK November 2020
• FRCP, Royal College of Physicians, Edinburgh, UK September 2020
• Clinical Fellowship, Osaka University Hospital, Japan March 2014
• Ph.D. ( Medical Science), Osaka University Graduate School of Medicine, Japan March 2014
• MBBS, Rajshahi University, Rajshahi Medical College, Bangladesh April 2004
Hossain's medical career began with roles as a Medical Officer at the Islami Bank Medical College, Rajshahi (IBMCR), and a DCH (Diploma in Child Health) Physician at Rajshahi Medical College Hospital (RMCH). In December 2008, he joined IBMCR, Bangladesh, as a registered and specialist physician in the Department of Pediatrics. Just four months later, Hossain transitioned to Khwaja Yunus Ali Medical College [6], Bangladesh, as a consultant paediatrician and assistant professor in the Department of Pediatrics.
Hossain's research journey on LSDs began during his Ph.D. studies at Osaka University (October 2009 - March 2014). He focused on various lysosomal storage diseases (LSDs), including Krabbe disease, Galactosialidosis, and Mucolipidosis. His doctoral thesis specifically explored Krabbe disease, investigating its pathophysiology (how it develops) and leading to the discovery of promising new therapeutic approaches for Krabbe and Galactosialidosis.
Following graduation, Hossain spent two years (2014-2016) in Saudi Arabia working as a Specialist Paediatric Doctor and Co-investigator at the King Abdullah Specialized Children’s Hospital and Research Center. He also maintained a collaborative relationship with Professor Norio Sakai [7] at Osaka University, which allowed him to continue publishing research initiated during his Ph.D. studies.
In 2016, Hossain returned to Japan to join the Advanced Clinical Research Center as a laboratory chief scientist. There, he worked alongside Prof. Yoshikatsu Eto. [8]
Eto's guidance opened doors for Hossain to explore a broader range of LSDs, including Fabry disease, Pompe disease, Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD), Neuronal Ceroid Lipofuscinosis (NCL), and Niemann-Pick disease type C (NPC). This diverse experience allowed him to make a significant contribution by uncovering a novel pathophysiological mechanism specifically affecting females with Fabry disease.
Since 2021, Hossain has been a medical advisor at JCR Pharmaceuticals Ltd. where their focus is on developing a next-generation enzyme replacement therapy (ERT) for various lysosomal storage diseases (LSDs). Current ERT treatments have limitations, as they are unable to reach the central nervous system (CNS) effectively and, therefore, cannot address neurocognitive impairment, a common symptom of many LSDs. JCR Pharmaceuticals is pioneering a new form of ERT (J-Brain Cargo), [9] specifically designed to target both the CNS and somatic organs. This advancement has the potential to significantly improve the lives of LSD patients by not only addressing their physical symptoms but also helping to maintain average growth and development [10]. Hossain's expertise in LSDs allows them to play a vital role in this groundbreaking effort.
In addition to his research achievements, Hossain has been recognized as a valuable speaker and mentor in the field of LSDs. Notably, he has been invited as a guest speaker at the International Symposium on Data Science [11] in NAIST and served as a mentor at the WORLDSymposium [12], the largest international conference on LSDs.
Member, Society for the Study of Inborn Errors of Metabolism (SSIEM) [18], Europe
Member, Japan Pediatrics Society [19]
Member, Japanese Society of Human Genetics [20]
Member, Japanese Society of Inherited Metabolic Diseases [21]
Life Member, Bangladesh Pediatrics Association [22]
Dr. Hossain has authored Chapter 6 of the book Krabbe Disease. Inherited metabolic diseases handbook (先天代謝異常ハンドブック). Published by Nakayama Shoten Co. Ltd. Volume 1, Issue 1 (2013). With Sakai N.
![]() | Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 3,201 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 19 May 2024 by
DoubleGrazing (
talk). The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you. This submission does not appear to be written in
the formal tone expected of an encyclopedia article. Entries should be written from a
neutral point of view, and should refer to a range of
independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid
peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. | ![]() |
Mohammad Arif Hossain | |
---|---|
![]() | |
Born | |
Citizenship | Japanese |
Education | Osaka University School of Medicine |
Employer | JCR pharmaceuticals ltd. |
Known for | Research on inherited metabolic diseases and Lysosomal storage disease |
Awards | JSIMD Young Investigator Award, 2019 |
Dr. Mohammad Arif Hossain, also known as Dr. Hossain, is a research scientist renowned for his contributions to the field of lysosomal storage disorders (LSDs). His research has led to advancements in diagnostic techniques and therapeutic approaches, including the development of chemical chaperone therapies and novel biomarker-based methods.
Hossain's research investigates lysosomal storage diseases (LSDs) and other Inborn errors of metabolism (IEMs), with a focus on improving diagnosis and treatment. His work has demonstrably contributed to understanding Krabbe disease, galactosialidosis, Fabry disease, and others. He has utilized patient-specific motor neurons derived from induced pluripotent stem cells (iPSCs) to study metachromatic leukodystrophy (MLD) and analyzed caregiver perspectives on treatment for mucopolysaccharidosis II (MPS II). Hossain has developed cellular models using patient-specific iPSCs to study Niemann-Pick disease type C (NPC) and established a diagnostic approach for X-linked adrenoleukodystrophy (X-ALD) in Japan. His research has yielded valuable insights into various LSDs and IEMs, including the therapeutic potential of genistein in mucolipidosis II and the characterization of enzymes for neuronal ceroid lipofuscinosis (NCL) types 1 and 2.
Hossain has authored more than 26 peer-reviewed articles. [1] in scientific journals. His efforts in uncovering the mechanisms and treatments for LSDs have earned him global recognition. He has been honored with the JSIMD Young Investigator Award [2] in 2019, the JHG Young Scientist Award in 2017 [3], and the Kunihiko Suzuki Award [4] in 2017.In 2020, he was awarded the World Symposium Young Investigator Award [5]
Since 2021 Hossain working as a medical advisor at JCR Pharmaceuticals Ltd. (JCRファーマ) to focus on developing enzyme replacement therapy (ERT) for various LSDs.
Hossain, was raised in a large Bangladeshi family with a strong emphasis on education, excelled academically. He pursued medicine, encountering diagnostic limitations in pediatrics that fueled his research drive. After a Ph.D. in Japan, his research focused on LSDs, leading to a novel therapeutic approach for Krabbe disease and Galactosialidosis.
Beyond science, Hossain's life reflects deep faith and a commitment to public health. He previously led an anti-smoking organization and actively promotes child health through media and online platforms. Currently residing in Japan with his family, he balances research with his role as a devoted husband and father.
• FRCP, Royal College of Physicians and Surgeons, Glasgow, UK September 2021
• FRCPCH, Royal College of Pediatrics and Child Health, London, UK November 2020
• FRCP, Royal College of Physicians, Edinburgh, UK September 2020
• Clinical Fellowship, Osaka University Hospital, Japan March 2014
• Ph.D. ( Medical Science), Osaka University Graduate School of Medicine, Japan March 2014
• MBBS, Rajshahi University, Rajshahi Medical College, Bangladesh April 2004
Hossain's medical career began with roles as a Medical Officer at the Islami Bank Medical College, Rajshahi (IBMCR), and a DCH (Diploma in Child Health) Physician at Rajshahi Medical College Hospital (RMCH). In December 2008, he joined IBMCR, Bangladesh, as a registered and specialist physician in the Department of Pediatrics. Just four months later, Hossain transitioned to Khwaja Yunus Ali Medical College [6], Bangladesh, as a consultant paediatrician and assistant professor in the Department of Pediatrics.
Hossain's research journey on LSDs began during his Ph.D. studies at Osaka University (October 2009 - March 2014). He focused on various lysosomal storage diseases (LSDs), including Krabbe disease, Galactosialidosis, and Mucolipidosis. His doctoral thesis specifically explored Krabbe disease, investigating its pathophysiology (how it develops) and leading to the discovery of promising new therapeutic approaches for Krabbe and Galactosialidosis.
Following graduation, Hossain spent two years (2014-2016) in Saudi Arabia working as a Specialist Paediatric Doctor and Co-investigator at the King Abdullah Specialized Children’s Hospital and Research Center. He also maintained a collaborative relationship with Professor Norio Sakai [7] at Osaka University, which allowed him to continue publishing research initiated during his Ph.D. studies.
In 2016, Hossain returned to Japan to join the Advanced Clinical Research Center as a laboratory chief scientist. There, he worked alongside Prof. Yoshikatsu Eto. [8]
Eto's guidance opened doors for Hossain to explore a broader range of LSDs, including Fabry disease, Pompe disease, Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD), Neuronal Ceroid Lipofuscinosis (NCL), and Niemann-Pick disease type C (NPC). This diverse experience allowed him to make a significant contribution by uncovering a novel pathophysiological mechanism specifically affecting females with Fabry disease.
Since 2021, Hossain has been a medical advisor at JCR Pharmaceuticals Ltd. where their focus is on developing a next-generation enzyme replacement therapy (ERT) for various lysosomal storage diseases (LSDs). Current ERT treatments have limitations, as they are unable to reach the central nervous system (CNS) effectively and, therefore, cannot address neurocognitive impairment, a common symptom of many LSDs. JCR Pharmaceuticals is pioneering a new form of ERT (J-Brain Cargo), [9] specifically designed to target both the CNS and somatic organs. This advancement has the potential to significantly improve the lives of LSD patients by not only addressing their physical symptoms but also helping to maintain average growth and development [10]. Hossain's expertise in LSDs allows them to play a vital role in this groundbreaking effort.
In addition to his research achievements, Hossain has been recognized as a valuable speaker and mentor in the field of LSDs. Notably, he has been invited as a guest speaker at the International Symposium on Data Science [11] in NAIST and served as a mentor at the WORLDSymposium [12], the largest international conference on LSDs.
Member, Society for the Study of Inborn Errors of Metabolism (SSIEM) [18], Europe
Member, Japan Pediatrics Society [19]
Member, Japanese Society of Human Genetics [20]
Member, Japanese Society of Inherited Metabolic Diseases [21]
Life Member, Bangladesh Pediatrics Association [22]
Dr. Hossain has authored Chapter 6 of the book Krabbe Disease. Inherited metabolic diseases handbook (先天代謝異常ハンドブック). Published by Nakayama Shoten Co. Ltd. Volume 1, Issue 1 (2013). With Sakai N.